Citigroup
AVBP icon

Citigroup’s ArriVent BioPharma AVBP Stock Holding History

Citigroup’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$172K Sell
7,435
-658
-8% -$14.9K ﹤0.01% 4068
2025
Q4 		$163K Sell
8,093
-1,944
-19% -$40.5K ﹤0.01% 4089
2025
Q3 		$185K Sell
10,037
-11,530
-53% -$227K ﹤0.01% 4023
2025
Q2 		$470K Sell
21,567
-12,602
-37% -$262K ﹤0.01% 3665
2025
Q1 		$632K Buy
34,169
+48
+0.1% +$1.18K ﹤0.01% 3548
2024
Q4 		$909K Buy
34,121
+13,721
+67% +$394K ﹤0.01% 3431
2024
Q3 		$479K Buy
20,400
+18,237
+843% +$414K ﹤0.01% 3757
2024
Q2 		$40.1K Buy
2,163
+422
+24% +$7.53K ﹤0.01% 4713
2024
Q1 		$31.1K Buy
+1,741
New +$35.1K ﹤0.01% 4879

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citigroup's AVBP Position: Q1 2026 in Review

Citigroup reduced its ArriVent BioPharma (AVBP) stake by 8.1% in Q1 2026, selling an estimated $14.9K and leaving 7,435 shares worth $172K. The position accounts for ﹤0.01% of the portfolio, ranked #4068.

Citigroup first reported a position in AVBP in Q1 2024 and has held it in 9 quarters since. The position peaked at $909K in Q4 2024. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Citigroup held 7,435 shares of ArriVent BioPharma worth $172K as of Q1 2026.
  • Citigroup sold 658 ArriVent BioPharma shares in Q1 2026, an estimated $14.9K.
  • ArriVent BioPharma made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4068 holding.
  • Citigroup first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 9 quarters since.
  • Citigroup's ArriVent BioPharma position peaked at $909K in Q4 2024.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.